Who Owns BioNTech Stock?
NASDAQ: BNTXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 20.45%
- Held by insiders
- 57.19%
- Institutional holders
- 477
- Institutions 20.4%
- Insiders 57.2%
- Public and other 22.4%
Who owns BioNTech stock?
Institutional investors own about 20.4% of BioNTech's shares, spread across 477 institutions that file 13F reports. That level of institutional ownership is relatively low, leaving more of the stock with retail investors and insiders. Insiders, including executives, directors and large founding shareholders, hold 57.19% of BNTX.
The largest institutional holders are FMR, LLC (2.99%), Primecap Management Company (1.49%) and Dodge & Cox Inc. (1.45%). Together, the top 10 institutions control 10.2% of shares outstanding. In their latest filings, 4 of the top 10 institutions increased their BNTX positions and 4 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of BNTX
| Institution | Shares | % Held | Change |
|---|---|---|---|
| FMR, LLC | 7.57M | 2.99% | +32.6% |
| Primecap Management Company | 3.77M | 1.49% | -0.6% |
| Dodge & Cox Inc. | 3.68M | 1.45% | +0.0% |
| Flossbach von Storch SE | 2.23M | 0.88% | -39.5% |
| T. Rowe Price Investment Management, Inc. | 2.07M | 0.82% | -64.7% |
| Blackrock Inc. | 1.85M | 0.73% | +11.9% |
| Temasek Holdings (Private) Ltd | 1.51M | 0.60% | 0.0% |
| BNP Paribas Financial Markets | 1.32M | 0.52% | -20.1% |
| Logos Global Management LP | 1.01M | 0.40% | +100.0% |
| GSK plc | 889.82K | 0.35% | 0.0% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of BNTX
| Fund | Shares | % Held |
|---|---|---|
| Fidelity Contrafund | 3.85M | 1.52% |
| Dodge & Cox Funds-Dodge & Cox International Stock Fund | 2.52M | 1.00% |
| VANGUARD HORIZON FUNDS-Vanguard Capital Opportunity Fund | 2.19M | 0.87% |
| T. Rowe Price Mid-Cap Growth Fund, Inc. | 1.02M | 0.40% |
| First TRT Exch-Trd Fd.-First TRT NYSE Arca Biotechnology Index Fd. | 989.58K | 0.39% |
| PRIMECAP Odyssey Funds-PRIMECAP Odyssey Aggressive Growth Fund | 897.16K | 0.35% |
| Fidelity Contrafund-Fidelity Contrafund K6 | 820.94K | 0.32% |
| Fidelity Investment Trust-Fidelity Emerging Markets Fund | 766.00K | 0.30% |
| iShares Trust-iShares Biotechnology ETF | 683.75K | 0.27% |
| Dodge & Cox Funds-Dodge & Cox Global Stock Fund | 525.78K | 0.21% |
Frequently asked questions
Who is the largest shareholder of BioNTech?
FMR, LLC is the largest institutional shareholder of BNTX, owning 2.99% of shares outstanding (7.57M shares) as of its latest 13F filing.
What percentage of BioNTech is owned by institutions?
Institutions own about 20.4% of BNTX shares and 47.8% of the public float.
How much of BioNTech do insiders own?
Insiders, such as officers and directors, own about 57.19% of BNTX shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.